Regional differences in performance of bone marrow transplantation, care-resource use and outcome for adult T-cell leukaemia in Japan

BMC Health Services Research

Kenji Fujimori¹  Kiyohide Fushimi⁴  Shinya Matsuda³  Takumi Nishi²  Akira Babazono²  Toshiki Maeda² 

[1]Department of Health Administration and Policy, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan

[2]Department of Healthcare Administration and Management, Graduate School of Healthcare Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

[3]Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, 1-1, Iseigaoka, Yahata-nishi-ku, Kitakyushu, Fukuoka 807-8555, Japan

[4]Department of Health Policy and Informatics, Tokyo Medical and Dental University, Graduate School of Medicine, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-0034, Japan

关键词: Hospital administrative database;    Outcome;    Care-resource;    Bone marrow transplantation;    Regional differences;    Adult T-cell leukaemia;   

Others  :  1126772
DOI  :  10.1186/1472-6963-14-337

 received in 2013-11-15, accepted in 2014-08-04,  发布年份 2014

【 摘 要 】

Background

Japan has a high prevalence of adult T-cell leukaemia (ATL), especially in the Kyushu/Okinawa region. Regional differences in prevalence might cause regional differences in physicians’ experiences and the efficiency of care-resource use. This study investigated regional differences in the performance of bone marrow transplantation (BMT), outcome and care-resource use in patients with ATL in Japan.

Methods

This was a cross-sectional study using a Japanese hospital administrative database in 2010, with a diagnostic-procedure combination/per diem payment system. We examined the association between BMT performance, resource use, outcomes and region.

Results

We analysed data for 712 subjects of whom 60.5% were Kyushu/Okinawa residents. Significantly more patients with ATL underwent BMT in Kanto (p = 0.018) and Kansai (p < 0.001) regions compared with the Kyushu/Okinawa regions. The lengths of hospital stay were longer in Kanto (p = 0.002) and Kansai (p = 0.006) regions than in the Kyushu/Okinawa region. Total health-care costs were higher in Kanto (p = 0.001) and Kansai (p = 0.005) regions than the Kyushu/Okinawa region. The risks of in hospital mortality were not significantly different between regions.

Conclusions

There were significant regional differences in BMT performance and resource use within Japan. ATL prevalence was not related to the performance of BMTs, resource use or outcomes. Factors related to regional socioeconomics might affect the performance of BMTs and care resource use within Japan.

【 授权许可】

   
2014 Maeda et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H: Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977, 50:481-492.
• [2]Takatsuki K: Discovery of adult T-cell leukemia. Retrovirology 2005, 2:16.
• [3]Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM: Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995, 332(26):1744-1748.
• [4]Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol 1991, 79(3):428-437.
• [5]Tsukasaki K, Hermine O, Bazarbachi A: Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009, 27(3):453-459.
• [6]Fernando AP, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL: Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005, 24:6058-6068.
• [7]Moriuchi H: The Research for Standardization of Health Guidance to Prevent HTLV-1 Maternal-Fetal Transmission. in Japanese: Ministry of Health, Labour and Welfare science research grant report; 2010.
• [8]Saito S: The Research for Prevention of HTLV-1 Maternal-Fetal Transmission. Japanese: Ministry of Health, Labour and Welfare science research grant report; 2009.
• [9]Yamaguchi K: The Comprehensive Survey of HTLV-1 Infection and HTLV-1 Associated Diseases. Japanese: Ministry of Health, Labour and Welfare science research grant report; 2009.
• [10]Comprehensive Strategy for HTLV-1 Infection. Ministry of Health, Labour and Welfare; 2010. http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou29/taisaku.html webcite (in Japanese, accessed Sep 05, 2013)
• [11]Gratwohl A, Baldomero H, Frauendorfer K, Niederwieser D, Joint Accreditation Committee of the International Society for Cellular Therapy ISCT; European Group for Blood and Marrow Transplantation EMBT (JACIE): Why are there regional differences in stem cell transplantation activity? An EBMT analysis. Bone Marrow Transplant 2008, 42:S7-S10. doi:10.1038/bmt.2008.104
• [12]Ikegami N, Yoo BK, Hashimoto H, Matsumoto M, Ogata H, Babazono A, Watanabe R, Shibuya K, Yang BM, Reich MR, Kobayashi Y: Japanese universal health coverage: evolution, achievements, and challenges. Lancet 2011, 378(9796):1106-1115. doi:10.1016/S0140-6736(11)60828-3. Epub 2011 Aug 30]
• [13]Matsuda S, Ishikawa KB, Kuwabara K, Fujimori K, Fushimi K, Hashimoto H: Development and use of the Japanese case-mix system. Euro Health 2008, 14(3):25-30.
• [14]Matsuda S: Casemix as a tool for transparency of medical services. Jpn J Social Secur Policy 2007., 6(1)
• [15]Japan Society for Hematopoietic Stem Cell Transplantation. http://www.jshct.com/english/ webcite (last access May21.2014)
• [16]Von Elm E, Altman DG, Egger M: Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370:1453-1457.
• [17]Sundararajana V, Hendersona T, Perrya C, Muggivana A, Quanb H, Ghali WA: New ICD-10 version of the Charlson Comorbidity Index predicted in-hospital mortality. J Clin Epidemiol 2004, 57:1288-1294.
• [18]Kuwabara K, Imanaka Y, Matsuda S, Fushimi K, Hashimoto H, Ishikawa KB, Horiguchi H, Hayashida K, Fujimori K: Impact of age and procedure on resource use for patients with ischemic heart disease. Health Policy 2008, 85(2):196-206.
• [19]Gratwohl A, Passweg J, Baldomero H, Bruno H: Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe. Br J Haematol 2002, 117:451-468.
• [20]Gratwohl A, Baldomero H, Schwendener A: Predictability of hematopoietic stem cell transplantation rates. Haematologica 2007, 92:1679-1686.
• [21]Guidance for Industry - Food and Drug Administration. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071590.pdf webcite (last access :May20.2014)
• [22]Thall PF, Champlin RE, Andersson BS: Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 2004, 33(12):1191-1199.
• [23]Weinstein MC, Skinner JA: Comparative effectiveness and health care spending–implications for reform. N Engl J Med 2010, 362(5):460-465. doi:10.1056/NEJMsb0911104. Epub 2010 Jan 6